Share Price | Eliem Therapeutics, Inc. Stock Analysis & Recommendation

Q: How big is Eliem Therapeutics, Inc.?

Market Cap: As of Jun 18, Eliem Therapeutics, Inc. has a market capitalization of 81.09 million, categorizing it as a Micro Cap company.Recent Quarterly Performance: For the latest four quarters, Eliem Therapeutics, Inc. reported net sales of 0.00 million and a net profit of -92.98 million.Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 211.88 million and total assets of 217.19 million.

Q: What does Eliem Therapeutics, Inc. do?

Overview:Eliem Therapeutics, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a micro-cap company.Financial Snapshot:Net Profit: -21 Million (Quarterly Results - Mar 2025) Market Cap: USD 81.09 Million (Micro Cap)Key Metrics:P/E: NA (Loss Making) Industry P/E: NA Dividend Yield: 0.00% Debt Equity: -0.51 Return on Equity: -19.64% Price to Book: 0.42 Contact Details:Details: No Company Details Available Registrar Address: Not available.

Q: Is Eliem Therapeutics, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Eliem Therapeutics, Inc. has changed from sideways to mildly bullish. The current stance is mildly bullish, driven by a bullish MACD on the weekly timeframe and a bullish daily moving average. However, the weekly RSI is bearish, indicating some short-term weakness. The Bollinger Bands show a mildly bullish signal on the weekly but are mildly bearish on the monthly, suggesting mixed signals. The KST is bullish weekly but bearish monthly, and Dow Theory indicates a mildly bearish stance on the weekly while being mildly bullish on the monthly.In terms of performance, Eliem Therapeutics has a year-to-date return of 24.44%, significantly outperforming the S&P 500's 12.22% during the same period, although it has underperformed over the past year with a return of -71.93% compared to the S&P 500's 17.14%.

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

512.64 k

Shareholding (Dec 2025)

FII

4.71%

Held by 33 FIIs

DII

78.98%

Held by 12 DIIs

Promoter

9.54%

How big is Eliem Therapeutics, Inc.?

22-Jun-2025

As of Jun 18, Eliem Therapeutics, Inc. has a market capitalization of 81.09 million, with net sales of 0.00 million and a net profit of -92.98 million over the last four quarters. The company reported shareholder's funds of 211.88 million and total assets of 217.19 million as of Dec 24.

View full answer

What does Eliem Therapeutics, Inc. do?

22-Jun-2025

Eliem Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $21 million and a market cap of $81.09 million. Key financial metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -0.51.

View full answer

Is Eliem Therapeutics, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Eliem Therapeutics, Inc. shows a mildly bullish trend with mixed signals from various indicators, having a year-to-date return of 24.44% compared to the S&P 500's 12.22%, but underperforming over the past year with a return of -71.93%.

View full answer

Compare Eliem Therapeutics, Inc. with Similar Stocks

Vaccinex, Inc.BioXcel Therapeutics, Inc.Athira Pharma, Inc.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Pharmaceuticals & Biotechnology

Market cap

USD 341 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.49

Return on Equity

-28.67%

Price to Book

1.92

Revenue and Profits:

Net Sales:

(Quarterly Results - Dec 2025)

Net Profit:

-18 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

42.17%

6 Months

190.67%

1 Year

403.08%

2 Years

132.74%

3 Years

99.69%

4 Years

-29.3%

5 Years

0.0%

Eliem Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

No Recent News for the Company

Announcements

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

-100.00%

EBIT Growth (5y)

-158.92%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.51

Sales to Capital Employed (avg)

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

72.73%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

1.92

EV to EBIT

-4.27

EV to EBITDA

-4.27

EV to Capital Employed

2.81

EV to Sales

PEG Ratio

Dividend Yield

ROCE (Latest)

-65.87%

ROE (Latest)

-28.67%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bearish

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Dec 2025

Shareholding Compare (%holding)

Majority shareholders

Strategic Entities

Domestic Funds

Held in 17 Schemes (6.77%)

Foreign Institutions

Held by 33 Foreign Institutions (4.71%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2025 is -108.33% vs -133.33% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.30",
          "val2": "-10.90",
          "chgp": "-77.06%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-17.50",
          "val2": "-8.40",
          "chgp": "-108.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 18.94% vs -110.54% in Dec 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-67.80",
          "val2": "-27.00",
          "chgp": "-151.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-55.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-59.90",
          "val2": "-73.90",
          "chgp": "18.94%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - YoY

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-19.30

-10.90

-77.06%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-17.50

-8.40

-108.33%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in quarter ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in quarter ended Dec 2025 is -108.33% vs -133.33% in Dec 2024

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'25

Dec'25

Dec'24

Change(%)

Net Sales

0.00

Operating Profit (PBDIT) excl Other Income

-67.80

-27.00

-151.11%

Interest

0.00

Exceptional Items

0.00

-55.00

100.00%

Consolidate Net Profit

-59.90

-73.90

18.94%

Operating Profit Margin (Excl OI)

0.00%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2025 is 0.00% vs 0.00% in Dec 2024

Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 18.94% vs -110.54% in Dec 2024

All Annual Results

Company CV

About Eliem Therapeutics, Inc.

Eliem Therapeutics, Inc.

Pharmaceuticals & Biotechnology

No Details Available.

Company Coordinates

No Company Details Available